Griner Erin M, Kazanietz Marcelo G
Department of Pharmacology and Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, USA.
Nat Rev Cancer. 2007 Apr;7(4):281-94. doi: 10.1038/nrc2110.
Almost three decades after the discovery of protein kinase C (PKC), we still have only a partial understanding of how this family of serine/threonine kinases is involved in tumour promotion. PKC isozymes - effectors of diacylglycerol (DAG) and the main targets of phorbol-ester tumour promoters - have important roles in cell-cycle regulation, cellular survival, malignant transformation and apoptosis. How do PKC isozymes regulate these diverse cellular processes and what are their contributions to carcinogenesis? Moreover, what is the contribution of all phorbol-ester effectors, which include PKCs and small G-protein regulators? We now face the challenge of dissecting the relative contribution of each DAG signal to cancer progression.
在蛋白激酶C(PKC)被发现近三十年后,我们对这个丝氨酸/苏氨酸激酶家族如何参与肿瘤促进作用仍只有部分了解。PKC同工酶——二酰基甘油(DAG)的效应器以及佛波酯肿瘤促进剂的主要靶点——在细胞周期调控、细胞存活、恶性转化和细胞凋亡中发挥着重要作用。PKC同工酶如何调节这些不同的细胞过程,它们对致癌作用有何贡献?此外,包括PKC和小G蛋白调节剂在内的所有佛波酯效应器的贡献是什么?我们现在面临着剖析每个DAG信号对癌症进展的相对贡献这一挑战。